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Abstract
Sarcoidosis is a chronic granulomatous multi-system dis-
ease with a clinical picture often mimicking tuberculosis.
We present a case of a patient who presented with a clini-
cal picture akin to both of these granulomatous disorders
and was started on anti-tuberculous regimen despite the
lack of any solid evidence pointing towards tuberculosis.
As a result her clinical condition continued to deteriorate
for months until finally a bronchoscopic biopsy established
her disease process as sarcoidosis. She was then started on
systemic corticosteroid therapy for sarcoidosis and during
the ensuing period has shown marked improvement in her
clinical picture with near normalization of the biochemical
and radiographic parameters of her pathology.
This case illustrates the need for vigilant interpreta-
tion of the clinical scenario in patients such as these where
a misdiagnosis may lead to significant patient 
distress as well as weighing down on the economic and
health resources.
Introduction
Sarcoidosis is a chronic systemic ailment prevalent
all over the world. Despite its widespread global distribu-
tion, there is considerable underrecognition, particularly in
the developing world. This holds particularly true for
regions endemic to tuberculosis, where sarcoidosis is being
overlooked as a possible diagnosis with increasing frequen-
cy, owing primarily to the similarities in the clinical and
radiological manifestations of the two pathologies. This
report presents a case of sarcoidosis which was continued
on anti-tuberculous regimen for several months, leading to
significant morbidity. Though not a rare scenario, this is
one which demands our urgent attention in order to gener-
ate an insight for the better understanding of this critical
issue.  
Case Report
A 50-year-old lady presented to pulmonary clinic
with a six month history of productive cough and evening
pyrexia. During this period she had lost around 33 pounds
weight and noticed a gradual reduction in her exercise tol-
erance. 
Her medical history was remarkable only for dia-
betes, under control on oral hypoglycaemics, and an expo-
sure to pulmonary tuberculosis in the past. 
On examination she appeared frail, though was
vitally stable. Chest auscultation revealed normal vesicular
breathing with no added sounds and equal bilateral air
entry. Laboratory investigations were within normal limits
apart from significantly elevated serum alkaline phos-
phatase and gamma glutamyl transferase, with values of
439 I.U. /L and 514 I.U. /L respectively. Sputum smear and
culture both were negative for acid fast bacilli. 
Chest X-ray revealed bilateral symmetrical hilar
lymphadenopathy with mild interstitial thickening (Figure
1). CT scan of the chest confirmed the adenopathy and
widespread miliary nodules (Figure 2).
In consideration of her clinical and radiographic
findings and the endemicity of tuberculosis in the region
she was started on four drug anti-tuberculosis therapy
(Isoniazid, Rifampicin, Ethambutol and Pyrazinamide).
Anti-tuberculosis therapy was continued for nearly seven
months. During this period there was cessation of her
evening rise in temperature. Apart from that there was no
noticeable improvement in her cough and she had lost
another two pounds in weight. Serial chest X-rays revealed
worsening of parenchymal infiltrates with no resolution of
the hilar adenopathy.
With the continuing deterioration of her clinical and
radiographic picture, a bronchoscopic biopsy was resorted
to. Histopathology of the biopsy specimen showed multiple
non-caseating granulomas composed of multinucleated
Figure 1. Chest X-ray shows bilateral symmetrical hilar lymphadenopathy with basal interstitial
thickening.
Figure 2. CT scan shows bilateral hilar lymphadenopathy, causing obstructive sub-segmental
atelectasis on the right. Tiny bilateral diffuse pulmonary nodules.
Figure 3. Photomicrograph of bronchial biopsy showing non-caseating granulomas along with
moderate chronic inflammation in sub-epithelial area. Note multi-nucleated giant cells. H&E stain
(Magnification x 100).
giant cells containing calcifications, in the subep-
ithelial fibrous tissue. Chronic granulomatous inflamma-
tion was confirmed (Figures 3 and 4) and special stains for
acid fast bacilli, fungi and other micro-organisms were
negative. Diagnosis of sarcoidosis was made and the
patient was started on Prednisolone therapy with concur-
rent discontinuation of the anti-tuberculous regimen. She
has continued her new treatment for nearly fifteen months
now. During this time she has gained nearly 36 lbs in
weight and complains no more of any respiratory or other
symptoms. Her liver enzyme levels have returned to nor-
mal and a recent chest radiograph revealed almost com-
plete resolution of the pulmonary infiltrates.
Discussion
Sarcoidosis is a chronic inflammatory systemic dis-
order of unknown etiology. It is characterized by the forma-
tion of non-caseating granulomas in the diseased tissues,
intrathoracic in 90% of the cases. Reported from all over
the world its frequency is influenced by race, gender, age
and the sophistication of regional medical care and screen-
ing programs, with genetic predisposition and infective
agent being other probable factors.
The clinical picture is variable among races and
includes constitutional symptoms as fever, fatigue, weight loss,
anorexia, cough and dyspnea. Hepatomegaly, splenomegaly
and lymphadenopathy are also seen. Common hematological
derangements include anemia, lymphopenia and raised ESR,
while hypercalcemia and hypergammaglobulinemia are also
recorded. Usual immunological findings encountered are
depression of cutaneous delayed-type hypersensitivity and an
increased T helper cell type response at disease sites. Signs of
B cell hyperactivity may also be seen along with circulating
immune complexes. 
In 90% to 95% of the patients there is an abnormal-
ity in chest radiographs at some point of time during the
course of their illness1, commonly lymphadenopathy.2
Classical radiological presentation is symmetric bilateral
hilar adenopathy with paratracheal adenopathy and the
characteristic bronchopulmonary adenopathy. Parenchymal
involvement is seen in a little less than half of the cases at
the time of presentation.1 Alveolar sarcoidosis is character-
ized by consolidative features (air-space opacities) fre-
quently accompanied by nodal involvement, as in this case.
Amongst imaging modalities, HRCT (High
Resolution Computed Tomography) is now the globally
preferred technique. CT scanning is superior to the chest X-
ray for studying both the adenopathy and the parenchymal
involvement. It also aids in the differential diagnosis of sar-
coidosis and other granulomatous disorders, especially
tuberculosis, and helps in following up for the detection of
any complications, like fibrosis.3 Nevertheless, chest X-ray
is still considered to be the most informative technique in
elucidating the disease activity.4
The elevated alkaline phosphatase and gamma glu-
tamyl transferase levels in our patient suggest probable
liver involvement by sarcoidosis. Incidence of hepatic
involvement amongst systemic manifestation of sarcoido-
sis is 66%.5 The liver enzyme values have been known to
normalize after appropriate therapy.6
Despite these advancements, there is still a global
underrecognition of the cases of sarcoidosis. This is owing
to the variable disease presentation, lack of consistent case
definition, lack of specific investigations and a dearth of
systemic epidemiological research in this direction. The
'great masquerader' should always be kept in mind in sce-
narios such as this one and others where the regional
endemicity and atypical clinical and radiological features
may point elsewhere. This is of particular relevance for the
developing world where tuberculosis is considered to be
endemic in a number of nations. The diagnosis of sarcoido-
sis should be made on carefully evaluated clinical and/or
radiological findings, histological evidence of noncaseat-
ing granulomas and exclusion of other diseases capable
of producing a similar histological or clinical picture. 
Even though cytotoxic agents have proven to be of
value in selected patients, corticosteroids are the drugs of
choice for the management of sarcoidosis.7 Although there
does exist controversy amongst the indications for the med-
ical therapy of sarcoidosis, standard therapy for sympto-
matic, progressive disease consists of corticosteroids.8
Prednisone is perhaps the most commonly used agent.
Other drugs have been used and found to be useful in vari-
ous clinical scenarios. Lung transplantation has been found
to be successful in end-stage disease with first year survival
Figure 4. Photomicrograph of bronchial biopsy showing non-caseating granulomas along with
moderate chronic inflammation in sub-epithelial area. Note multi-nucleated giant cells. The respi-
ratory surface epithelium is unremarkable. H&E Stain (Magnification x 200).
useful in various clinical scenarios. Lung transplan-
tation has been found to be successful in end-stage disease
with first year survival rates comparable to other forms of
diffuse lung diseases.9
The clinical course of sarcoidosis is variable. Most
persons with sarcoidosis have spontaneous remission of
their disease, although between 10% and 30% may be
afflicted with chronic or progressive disease.10 The health
related quality of life is globally diminished. Mortality is
usually owing to pulmonary and cardiac complications.
In conclusion our patient is a typical case in which
sarcoidosis was initially overlooked as a possible diagnosis
and anti-tuberculosis therapy initiated despite the absence
of solid evidence towards tuberculosis. This is a common
practice in many territories endemic for tuberculosis and
has contributed towards increasing the burden of disease in
many developing regions of the world. This highlights
again the need for careful evaluation of the clinical and
radiologic evidence in all typical and atypical presentation
patterns of sarcoidosis.  
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